Literature DB >> 26776846

Indications for staging laparoscopy in pancreatic cancer.

Antonella De Rosa1, Iain C Cameron1, Dhanwant Gomez2.   

Abstract

BACKGROUND: To identify indications for staging laparoscopy (SL) in patients with resectable pancreatic cancer, and suggest a pre-operative algorithm for staging these patients.
METHODS: Relevant articles were reviewed from the published literature using the Medline database. The search was performed using the keywords 'pancreatic cancer', 'resectability', 'staging', 'laparoscopy', and 'Whipple's procedure'.
RESULTS: Twenty four studies were identified which fulfilled the inclusion criteria. Of the published data, the most reliable surrogate markers for selecting patients for SL to predict unresectability in patients with CT defined resectable pancreatic cancer were CA 19.9 and tumour size. Although there are studies suggesting a role for tumour location, CEA levels, and clinical findings such as weight loss and jaundice, there is currently not enough evidence for these variables to predict resectability. Based on the current data, patients with a CT suggestive of resectable disease and (1) CA 19.9 ≥150 U/mL; or (2) tumour size >3 cm should be considered for SL.
CONCLUSION: The role of laparoscopy in the staging of pancreatic cancer patients remains controversial. Potential predictors of unresectability to select patients for SL include CA 19.9 levels and tumour size.
Copyright © 2015 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26776846      PMCID: PMC4750228          DOI: 10.1016/j.hpb.2015.10.004

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  75 in total

1.  Pain as a predictor of outcome in patients with operable pancreatic carcinoma.

Authors:  D P Kelsen; R Portenoy; H Thaler; Y Tao; M Brennan
Journal:  Surgery       Date:  1997-07       Impact factor: 3.982

2.  Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis.

Authors:  Shandra Bipat; Saffire S K S Phoa; Otto M van Delden; Patrick M M Bossuyt; Dirk J Gouma; Johan S Laméris; Jaap Stoker
Journal:  J Comput Assist Tomogr       Date:  2005 Jul-Aug       Impact factor: 1.826

3.  The pathology of pancreatic cancer and its possible relationship to pain.

Authors:  P J Fitzgerald
Journal:  J Pain Symptom Manage       Date:  1988       Impact factor: 3.612

Review 4.  Laparoscopy in the staging of pancreatic cancer.

Authors:  P W Pisters; J E Lee; J N Vauthey; C Charnsangavej; D B Evans
Journal:  Br J Surg       Date:  2001-03       Impact factor: 6.939

5.  The prognostic effect of clinical staging in pancreatic adenocarcinoma.

Authors:  Alessio G Morganti; M Gabriella Brizi; Gabriella Macchia; Giuseppina Sallustio; Guido Costamagna; Sergio Alfieri; Gian Carlo Mattiucci; Vincenzo Valentini; Luigi Natale; Francesco Deodato; Massimiliano Mutignani; G Battista Doglietto; Numa Cellini
Journal:  Ann Surg Oncol       Date:  2005-02-04       Impact factor: 5.344

Review 6.  CA 19-9 in pancreatic cancer.

Authors:  R E Ritts; H A Pitt
Journal:  Surg Oncol Clin N Am       Date:  1998-01       Impact factor: 3.495

Review 7.  Pancreatic cancer. Laparoscopic staging and peritoneal cytology.

Authors:  C L Fernández-del Castillo; A L Warshaw
Journal:  Surg Oncol Clin N Am       Date:  1998-01       Impact factor: 3.495

8.  Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.

Authors:  R R White; H I Hurwitz; M A Morse; C Lee; M S Anscher; E K Paulson; M R Gottfried; J Baillie; M S Branch; P S Jowell; K M McGrath; B M Clary; T N Pappas; D S Tyler
Journal:  Ann Surg Oncol       Date:  2001-12       Impact factor: 5.344

9.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

10.  A proposed model for prediction of survival based on a follow-up study in unresectable pancreatic cancer.

Authors:  Henrik Forssell; Michael Wester; Katrin Akesson; Sigrid Johansson
Journal:  BMJ Open       Date:  2013-12-17       Impact factor: 2.692

View more
  16 in total

1.  The Yield of Staging Laparoscopy in Gastric Cancer is Affected by Racial and Ethnic Differences in Disease Presentation.

Authors:  Ibrahim Nassour; Hannah Fullington; Linda S Hynan; Adam C Yopp; Mathew M Augustine; Patricio M Polanco; Michael A Choti; John C Mansour; Sam C Wang; Matthew R Porembka
Journal:  Ann Surg Oncol       Date:  2017-02-13       Impact factor: 5.344

2.  Oncolytic Virotherapy Increases the Detection of Microscopic Metastatic Disease at Time of Staging Laparoscopy for Pancreatic Adenocarcinoma.

Authors:  Christopher J LaRocca; Julia Davydova
Journal:  EBioMedicine       Date:  2016-05-19       Impact factor: 8.143

Review 3.  The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic.

Authors:  Thinzar M Lwin; Robert M Hoffman; Michael Bouvet
Journal:  Expert Rev Anticancer Ther       Date:  2018-05-28       Impact factor: 4.512

4.  Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study.

Authors:  Guolan Lu; Nynke S van den Berg; Brock A Martin; Naoki Nishio; Zachary P Hart; Stan van Keulen; Shayan Fakurnejad; Stefania U Chirita; Roan C Raymundo; Grace Yi; Quan Zhou; George A Fisher; Eben L Rosenthal; George A Poultsides
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-05-14

Review 5.  Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer.

Authors:  Xiao Sun; Xiaobin Zhou; Yuan Zhang; Xiaoyan Zhu; Haihua Liu
Journal:  Dis Markers       Date:  2018-05-15       Impact factor: 3.434

6.  Retrospective Study of the Correlation Between Pathological Tumor Size and Survival After Curative Resection of T3 Pancreatic Adenocarcinoma: Proposal for Reclassification of the Tumor Extending Beyond the Pancreas Based on Tumor Size.

Authors:  Masanao Kurata; Goro Honda; Yoshiaki Murakami; Kenichiro Uemura; Sohei Satoi; Fuyuhiko Motoi; Masayuki Sho; Ippei Matsumoto; Manabu Kawai; Hiroaki Yanagimoto; Takumi Fukumoto; Minako Nagai; Masahiko Gosho; Michiaki Unno; Hiroki Yamaue
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

7.  Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer.

Authors:  Xinchun Liu; Yue Fu; Qiuyang Chen; Junli Wu; Wentao Gao; Kuirong Jiang; Yi Miao; Jishu Wei
Journal:  BMC Gastroenterol       Date:  2018-11-06       Impact factor: 3.067

8.  Combined modality therapy including cytoreductive surgery and heated intraperitoneal chemotherapy for synchronous low volume peritoneal carcinomatosis from adenocarcinoma of the tail of pancreas in a BRCA-2 carrier resulting in long-term disease-free survival: A case report.

Authors:  Richard A Hoefer; Chukwuemeka Obiora; Basem Azab; Elizabeth A Harden; John F Kessler
Journal:  Int J Surg Case Rep       Date:  2021-05-29

9.  Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.

Authors:  William H Sherman; Elizabeth Hecht; David Leung; Kyung Chu
Journal:  Oncologist       Date:  2017-12-06

10.  Specific detection of soluble EphA2 fragments in blood as a new biomarker for pancreatic cancer.

Authors:  Naohiko Koshikawa; Tomoko Minegishi; Hirofumi Kiyokawa; Motoharu Seiki
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.